Gamifant recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis.- Sobi
Sobi announces that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
Primary HLH is an ultra-rare, life-threatening, hyperinflammatory disorder, characterised by uncontrolled activation of the immune system. Morbidity and mortality are high due to lack of detection and non-specific symptoms, but if diagnosed early and appropriately treated, the inflammation and damage can be reduced. Gamifant represents a treatment option for patients with progressive disease through a targeted mode of action.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.